Bomb Report – Lifestyle
Author:
ALEBUND
Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
May 6, 2026
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
March 17, 2026